Norway-based clinical-stage biotechnology company Ultimovacs (OSE:ULTI) announced on Monday that it has secured Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its UV1 cancer vaccine in mesothelioma, supported by positive results from the NIPU Phase II trial.
UV1 has also received ODD from the US Food and Drug Administration (FDA) for treating mesothelioma and malignant melanoma stages IIB to IV.
In the EU, ODD provides exclusive market rights for 10 years, clinical protocol assistance, centralised marketing authorisation and reduced regulatory fees.
Mesothelioma, often linked to asbestos exposure, lacks effective treatments, making UV1's approval significant. The NIPU trial demonstrated UV1's efficacy in combination with ipilimumab and nivolumab, showing improved overall survival without added toxicities.
Recently approved Fast Track designation from the FDA further accelerates UV1's path to approval, marking potentially significant progress in mesothelioma treatment.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration